- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated good antiretroviral activity and tolerability as 7-day monotherapy in a small Phase 1b trial, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
Matt Anderson from Merck summarized the study findings at a CROI press conference on Antiretroviral Therapy: New Agents and New Insights.
[Matt Anderson speaks at CROI 2013 press conference, Atlanta, March 5, 2013]
M Anderson, J Gilmarti, M Robberechts, et al. Safety and Antiviral Activity of MK-1439, a Novel NNRTI, in Treatment-naive HIV+ Patients. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 100.